William Aragonés Sanzen-Baker, José Miguel Villacampa Aubá, Ignacio Alcalá Rueda, Jessica Mireya Santillán Coello, Gonzalo Díaz Tapia, Carlos Cenjor Español, Álvaro Sánchez Barrueco
{"title":"Stratification of the severity of Chronic Obstructive Sialadenitis based on its impact on Quality of Life.","authors":"William Aragonés Sanzen-Baker, José Miguel Villacampa Aubá, Ignacio Alcalá Rueda, Jessica Mireya Santillán Coello, Gonzalo Díaz Tapia, Carlos Cenjor Español, Álvaro Sánchez Barrueco","doi":"10.1016/j.otoeng.2025.512223","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic Obstructive Sialadenitis (COS) is a debilitating condition characterized by recurrent inflammation of the salivary glands due to excretory obstruction, significantly impacting patients' quality of life (QoL). The COS Quality of Life Questionnaire (COSQ) has been validated to evaluate QoL in affected patients and to monitor changes post-treatment.</p><p><strong>Materials and methods: </strong>This study included two patient groups with COS-affected glands. The first group of 342 patients completed the COSQ before minimally invasive surgery, while the second group of 215 patients completed both the COSQ and a Visual Analog Scale (VAS). Scores were analyzed and stratified into four severity categories: mild, moderate, severe, and very severe, based on COSQ outcomes.</p><p><strong>Results: </strong>COSQ scores were distributed as follows: mild (12.87%), moderate (37.13%), severe (34.5%), and very severe (15.21%). A significant correlation was observed between COSQ and VAS scores, particularly in the moderate and severe categories. Stratification allowed for identification of patients with severe symptoms, aiding in tailored management.</p><p><strong>Conclusion: </strong>The COSQ effectively assesses QoL in COS patients and aids in stratifying severity. This stratification can guide clinicians in developing personalized treatment strategies, monitoring disease progression, and evaluating treatment outcomes.</p>","PeriodicalId":93855,"journal":{"name":"Acta otorrinolaringologica espanola","volume":" ","pages":"512223"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.otoeng.2025.512223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Chronic Obstructive Sialadenitis (COS) is a debilitating condition characterized by recurrent inflammation of the salivary glands due to excretory obstruction, significantly impacting patients' quality of life (QoL). The COS Quality of Life Questionnaire (COSQ) has been validated to evaluate QoL in affected patients and to monitor changes post-treatment.
Materials and methods: This study included two patient groups with COS-affected glands. The first group of 342 patients completed the COSQ before minimally invasive surgery, while the second group of 215 patients completed both the COSQ and a Visual Analog Scale (VAS). Scores were analyzed and stratified into four severity categories: mild, moderate, severe, and very severe, based on COSQ outcomes.
Results: COSQ scores were distributed as follows: mild (12.87%), moderate (37.13%), severe (34.5%), and very severe (15.21%). A significant correlation was observed between COSQ and VAS scores, particularly in the moderate and severe categories. Stratification allowed for identification of patients with severe symptoms, aiding in tailored management.
Conclusion: The COSQ effectively assesses QoL in COS patients and aids in stratifying severity. This stratification can guide clinicians in developing personalized treatment strategies, monitoring disease progression, and evaluating treatment outcomes.